Related content

Generation of dendritic cell–tumor cell hybrids by electrofusion for clinical vaccine application

By Trevor Katrina   Cover Cathleen   Ruiz Yvette   Akporiaye Emmanuel   Hersh Evan   Landais Didier   Taylor Rachel   King Alan   Walters Richard  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 8, 2004-08 ,pp. : 705-714

Springer Publishing Company

Access to resources Recommend Favorite

Dendritic cell–tumor cell hybrid vaccination for metastatic cancer

By Barbuto Jose   Ensina Luis   Neves Andreia   Bergami-Santos Patrícia   Leite Katia   Marques Ricardo   Costa Frederico   Martins Siderleny   Camara-Lopes Luiz   Buzaid Antonio  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 12, 2004-12 ,pp. : 1111-1118

Springer Publishing Company

Access to resources Recommend Favorite

Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT

By Ou Xueling   Cai Shaohui   Liu Peng   Zeng Jun   He Yuwen   Wu Xinyao   Du Jun  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 5, 2008-05 ,pp. : 525-533

Springer Publishing Company

Access to resources Recommend Favorite

Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses

By Lundqvist Andreas   Palmborg Andreas   Bidla Gawa   Whelan Mike   Pandha Hardev   Pisa Pavel  

Medical Oncology, Vol. 21, Iss. 2, 2004-06 ,pp. : 155-165

Humana Press, Inc

Access to resources Recommend Favorite

Allogeneic Tumor Vaccine Produced by Electrofusion between Osteosarcoma Cell Line and Dendritic Cells in the Induction of Antitumor Immunity

By Yu Zhe   Ma Bao'an   Zhou Yong   Zhang Minghua   Long Hua   Wang Yucai   Fan Qingyu  

Cancer Investigation, Vol. 25, Iss. 7, 2007-10 ,pp. : 535-541

Informa Healthcare

Access to resources Recommend Favorite